AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32544361
Drug: bivalent HPV‐16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent HPV‐16/18 vaccine with a 2nd interval of 103–139 d
Trial: 32544361
Drug: bivalent HPV‐16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent HPV‐16/18 vaccine with a 2nd interval of 140–160 d
Trial: 32544361
Drug: bivalent HPV‐16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent HPV‐16/18 vaccine with a 2nd interval of 161–198 d
Trial: 32115477
Drug: Nalmefene 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 20 mg
Trial: 32145041
Drug: morphine-naloxone 100:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine-naloxone 100:1 (75 mg: 0.75 mg)
Trial: 32145041
Drug: morphine-naloxone 200:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine-naloxone 200:1 (75 mg: 0.375 mg)
Trial: 32145041
Drug: morphine mono
RxNorm normalized name: Morphine monomethyl ether
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine mono (75 mg)
Trial: 33279603
Drug: Enteric-coated fast
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated fast release formulation
Trial: 33058774
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) dexamethasone
Trial: 35380237
Drug: Control (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Treatment as Usual, TAUG, n = 8)
Trial: 32212354
Drug: Oral Feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Feeding (OF)
Trial: 34077509
Drug: Risankizumab 180
RxNorm normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 180 mg every 8 weeks
Trial: 34077509
Drug: Risankizumab 600
RxNorm normalized name: RISANKIZUMAB 600 mg in 10 mL INTRAVENOUS INJECTION [Skyrizi]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 600 mg every 4 weeks (for reinduction of four patients)
Trial: 34125259
Drug: i-gel laryngeal
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel laryngeal mask airway
Trial: 35514364
Drug: Home-based NMES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based NMES therapy
Trial: 33909052
Drug: Informed consent
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informed consent documents from COVID-19 vaccine trials
Trial: 32591433
Drug: ChAdOx1-MVA 5T4
RxNorm normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1-MVA 5T4 vaccine
Trial: 33078646
Drug: Multi-vitamin-mineral supplement
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-vitamin-mineral supplement (MVMS)
Trial: 32538835
Drug: Increased serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased serum calcium level (per 1 standard deviation (SD) increase 0.5 mg/dL)
Trial: 34271963
Drug: Single-agent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent oral selinexor
Trial: 32535481
Drug: Abelmoschus manihot
RxNorm normalized name: ABELMOSCHUS MANIHOT WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelmoschus manihot (AM) 2.5 g three times per day for 48 weeks
Trial: 32535481
Drug: losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan potassium 100 mg per day for 48 weeks
Trial: 34636000
Drug: Upadacitinib monotherapy
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib monotherapy
Trial: 35919945
Drug: Upadacitinib plus
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib plus csDMARD therapy
Trial: 35919945
Drug: csDMARD-only therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: csDMARD-only therapy
Trial: 35919945
Drug: bDMARD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bDMARD plus csDMARD therapy
Trial: 33257661
Drug: 10-mg oral
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-mg oral methotrexate once weekly with daily 5-mg folic acid for 12 weeks
Trial: 33257661
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo with daily 5-mg folic acid for 12 weeks
Trial: 32139496
Drug: Nurse-delivered sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-delivered sleep restriction therapy (SRT) plus sleep hygiene booklet
Trial: 33556413
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg/day (n = 32)
Trial: 33556413
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg/day (n = 32) in statin non-users
Trial: 35184326
Drug: Low-dose aripiprazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aripiprazole adjunctive to antidepressant therapy
Trial: 33429750
Drug: Bosentan combined
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan combined with vardenafil oral group
Trial: 33429750
Drug: Vardenafil oral
RxNorm normalized name: vardenafil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil oral group
Trial: 36272432
Drug: Molnupiravir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir (800 mg orally, twice daily for 5 days)
Trial: 34399982
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium nitrate (700 mg×2)
Trial: 33139276
Drug: Tribendimidine monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine monotherapy
Trial: 33232172
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose pill)
Trial: 33075067
Drug: Intensive MDA
RxNorm normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive MDA (quarterly single-dose praziquantel 40mg/kg; triple-dose albendazole 400mg)
Trial: 33075067
Drug: Standard Uganda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Uganda government intervention (annual single-dose praziquantel 40mg/kg; 6-monthly single-dose albendazole)
Trial: 34086129
Drug: Distrust of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distrust of vaccine safety and general vaccine avoidance
Trial: 32085633
Drug: Birch pollen
RxNorm normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch pollen immunotherapy
Trial: 34966141
Drug: Azithromycin at
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin at 10 mg/kg/d
Trial: 34966141
Drug: Doxycycline at
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline at 4.4 mg/kg/d for 5 days
Trial: 35732989
Drug: hBO‐HD (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hBO‐HD (640 mg)
Trial: 35732989
Drug: hBO‐MD (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hBO‐MD (320 mg)
Trial: 35732989
Drug: hBO‐LD (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hBO‐LD (160 mg)
Trial: 36239756
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks
Trial: 32789966
Drug: Raltitrexed (RTX)
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (RTX) 2 mg/m2 every 2 weeks
Trial: 32789966
Drug: Raltitrexed (RTX)
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (RTX) 3 mg/m2 every 3 weeks
Trial: 32152817
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine lymphedema treatments)
Trial: 33858397
Drug: Hemoglobin concentration
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin concentration (g/dL)
Trial: 33428786
Drug: Hyperthermic intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (460 mg/m2) and docetaxel (in escalating doses) after preoperative systemic chemotherapy and surgical procedure.
Trial: 33155417
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (specific drug not mentioned)
Trial: 33155417
Drug: Censoring at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Censoring at initiation of subsequent therapy
Trial: 33155417
Drug: Considering recurrence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Considering recurrence or progression events (including death) before and after initiation of subsequent therapy
Trial: 33155417
Drug: Considering the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Considering the start of subsequent therapy as an event
Trial: 32618265
Drug: Mass Drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Drug Administration (MDA) with dihydroartemisinin‐piperaquine (DHAP)
Trial: 33340154
Drug: Medical grade
RxNorm normalized name: Skarcade Medical Grade Silicone Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical grade honey gel (L-Mesitran Soft®) applied intraoperatively on the linea alba
Trial: 33340154
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medical grade honey gel)
Trial: 33340154
Drug: Medical grade
RxNorm normalized name: Skarcade Medical Grade Silicone Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical grade honey gel (L-Mesitran Soft®)
Trial: 34547261
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg tablet dissolved in apple juice)
Trial: 34547261
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL of apple juice)
Trial: 36301338
Drug: Daratumumab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab 16 mg/kg
Trial: 33388991
Drug: Turbinate outfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbinate outfracture in combination with radiofrequency ablation
Trial: 33833225
Drug: Psilocybin (0.17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (0.17 mg/kg)
Trial: 32701929
Drug: Leukocyte‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte‐ and platelet‐rich fibrin (L‐PRF) used to fill and cover extraction sockets (n=11, Test Group)
Trial: 32701929
Drug: No L‐PRF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No L‐PRF used (n=12, Control Group)
Trial: 38674803
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 6 months
Trial: 35708992
Drug: Solution‐Focused Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution‐Focused Group Psychoeducation
Trial: 33293316
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II type 1 receptor blockers (ARBs)
Trial: 34228172
Drug: Self-reported symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported symptoms after treatment
Trial: 32278781
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of immediate-release venlafaxine
Trial: 34138909
Drug: Antibody titer
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody titer testing
Trial: 33026175
Drug: 160 IU
RxNorm normalized name: Ascorbic Acid/Copper/Vitamin A/Vitamin E/Zinc 113 MG-0.4 MG-7160 IU-100 IU-17.4 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 IU intranasal insulin (IN-INS)
Trial: 36092515
Drug: Gum Arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum Arabic (GA) powder, applied twice a day for 60 days.
Trial: 36092515
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose powder (placebo), applied twice a day for 60 days.
Trial: 32438420
Drug: Sham interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham interventions (e.g., saline injections into spinal structures, peripheral nerves, cranial surgery, spine surgery)
Trial: 37077927
Drug: 2.5% BPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% BPO gel
Trial: 32205769
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic treatment (ABT) per PEG protocol (n=78)
Trial: 32706674
Drug: Self-directed web-based
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed web-based education and exercise therapy for 6 weeks
Trial: 32706674
Drug: Physiotherapist-led education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapist-led education and exercise therapy (face-to-face or telerehabilitation) for 12 weeks
Trial: 33782552
Drug: Pharmacogenetic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic testing for medications managing acute and chronic pain and depression
Trial: 33509394
Drug: Hemoglobin drop
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin drop (minor: ≥3 and <5 g/dl) without overt bleeding
Trial: 33509394
Drug: Hemoglobin drop
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin drop (major: ≥5 g/dl) without overt bleeding
Trial: 33509394
Drug: Hemoglobin drop
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin drop (minor: ≥3 and <5 g/dl) with overt bleeding
Trial: 33509394
Drug: Hemoglobin drop
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin drop (major: ≥5 g/dl) with overt bleeding
Trial: 35577476
Drug: Systemic lidocaine
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic lidocaine (1.5 mg/kg bolus, followed by 1.5 mg/kg/hour infusion until the end of surgery)
Trial: 33615769
Drug: Electric toothbrush/irrigator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electric toothbrush/irrigator combination (test)
Trial: 32807241
Drug: LMWH +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH + steroid group
Trial: 32807241
Drug: UFH +
RxNorm normalized name: Unfractionated Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UFH + steroid group
Trial: 36206400
Drug: Belimumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (1, 4, or 10 mg/kg intravenous or 200 mg subcutaneous) plus standard therapy
Trial: 32131611
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg low-dose aspirin (COX-1 inhibitor) for 2 weeks
Trial: 33492500
Drug: Oral hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrocortisone sodium succinate and aluminum phosphate gel (OHA)
Trial: 33492500
Drug: Endoscopic loco-regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic loco-regional triamcinolone acetonide injection (ETI) plus oral prednisone
Trial: 33492500
Drug: ETI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETI plus oral prednisone
Trial: 34455688
Drug: Prehospital antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital antiplatelet therapy
Trial: 34455688
Drug: Non-antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antiplatelet therapy
Trial: 32372486
Drug: Nitrate treatment
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate treatment (various preparations and doses)
Trial: 32372486
Drug: Nitrate treatment
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate treatment (pooled active treatment groups)
Trial: 35860190
Drug: Shenling Chengqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenling Chengqi decoction combined with routine treatment for 7 days
Trial: 33105277
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia of 20% sevoflurane emulsion
Trial: 33105277
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia of sevoflurane
Trial: 35112178
Drug: Local periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local periarticular infiltration anaesthesia (LIA) with 60 ml of ropivacaine 0.5% and 1 ml of dexmedetomidine (100 µg ml‐1)
Trial: 35112178
Drug: Ultrasound-guided regional
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided regional anaesthesia (USRA) with two single-shot femoral and popliteal blocks, each with 15 ml of ropivacaine 0.5% and 0.5 ml of dexmedetomidine
Trial: 33784802
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone 2.5 mg
Trial: 33784802
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone 5 mg
Trial: 35439347
Drug: Rezafungin 10
RxNorm normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezafungin 10 mg single subcutaneous dose
Trial: 35439347
Drug: Rezafungin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezafungin (various doses: 1, 10, 30, 60, 100, or 200 mg)
Trial: 33706186
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of perindopril, indapamide, and amlodipine
Trial: 35283313
Drug: ChAdOx1 followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ChAdOx1 followed by a mRNA vaccine
Trial: 33337904
Drug: Psychological behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological behaviour management programme (including symbolic modelling, tell‐show‐do, positive reinforcement, distraction) during the second treatment
Trial: 33337904
Drug: Watching cartoon
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watching cartoon animations during the first treatment and control group during the second treatment
Trial: 35293006
Drug: D‐VCd followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐VCd followed by daratumumab monotherapy
Trial: 33285469
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 12 months)
Trial: 34449185
Drug: Abbreviated therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated therapy (1 month of dual antiplatelet therapy)
Trial: 34449185
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (continuation of dual antiplatelet therapy for at least 2 additional months)
Trial: 35713517
Drug: Pyrotinib and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib and trastuzumab with weekly paclitaxel-cisplatin neoadjuvant chemotherapy for four cycles
Trial: 34927293
Drug: M100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M100 (100 g ML powder per sow per day)
Trial: 34927293
Drug: M200 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M200 (200 g ML powder per sow per day)
Trial: 34927293
Drug: M300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M300 (300 g ML powder per sow per day)
Trial: 34927293
Drug: M400 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M400 (400 g ML powder per sow per day)